272 related articles for article (PubMed ID: 25446566)
1. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
2. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
[TBL] [Abstract][Full Text] [Related]
3. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
[TBL] [Abstract][Full Text] [Related]
4. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Matera MG
Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
[TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
6. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
7. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.
Calzetta L; Rogliani P; Page C; Rinaldi B; Cazzola M; Matera MG
Pulm Pharmacol Ther; 2019 Jun; 56():39-50. PubMed ID: 30876907
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
10. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L
Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611
[TBL] [Abstract][Full Text] [Related]
11. Interaction between corticosteroids and muscarinic antagonists in human airways.
Cazzola M; Calzetta L; Rogliani P; Puxeddu E; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2016 Feb; 36():1-9. PubMed ID: 26656790
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
13. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG
COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Calzetta L; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
[TBL] [Abstract][Full Text] [Related]
16. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.
D'Urzo AD; Singh D; Donohue JF; Chapman KR
Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854
[TBL] [Abstract][Full Text] [Related]
17. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
Calzetta L; Cazzola M; Page CP; Rogliani P; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2015 Jun; 32():15-23. PubMed ID: 25899618
[TBL] [Abstract][Full Text] [Related]
19. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
Blasi F; Canonica GW; Miravitlles M
Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244
[TBL] [Abstract][Full Text] [Related]
20. Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP.
Lambers C; Costa L; Ying Q; Zhong J; Lardinois D; Dekan G; Schuller E; Roth M
Pharmacol Res; 2015 Dec; 102():310-8. PubMed ID: 26546746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]